Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin

摘要: Background: The clinical efficacy and safety of Endostar combined with chemotherapy in the treatment metastatic malignant melanoma (MM) were analyzed indicators capable predicting regimen identified to guide practice. Patients methods: data 55 patients MM without gene mutations who treated dacarbazine cisplatin retrospectively analyzed. Efficacy was assessed using RECIST 1.1, adverse events (AEs) graded according NCI-CTCAE 4.0. log-rank test used compare survival curves different subgroups, stepwise multivariate Cox regression analysis determine significant prognostic factors. Differences considered statistically at P<0.05. Results: Of patients, seven showed a partial response, 20 stable disease, 28 progressive disease. median progression-free 17.9 months. AEs controllable. Univariate biotherapy, stage, classification, low baseline platelet count, albumin ratio (PAR), globulin (PGR) as factors affecting drug efficacy. Multivariate stage PAR independent regimen. Conclusions: curative effect on mutations, count derived PGR values associated regimen. potential value prediction remains be further verified by prospective random experiments.